ESPR Stock Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Esperion Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.23 |
| 52 Week High | US$8.87 |
| 52 Week Low | US$0.70 |
| Beta | 0.30 |
| 1 Month Change | 58.79% |
| 3 Month Change | -24.54% |
| 1 Year Change | -81.34% |
| 3 Year Change | -95.66% |
| 5 Year Change | -97.86% |
| Change since IPO | -91.52% |
Recent News & Updates
Recent updates
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022
Jan 20Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection
Oct 27Esperion: Hunting Big Game In The Danger Zone
Aug 05Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year
May 09Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 04Esperion Therapeutics: Deeply Undervalued With An Extremely High Short Interest
Jan 30Esperion Therapeutics (ESPR) Presents At 39th Annual Healthcare Conference - Slideshow
Jan 14Bullish: Analysts Just Made A Significant Upgrade To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Jan 14
Esperion announces deal with Serometrix and gives out Q4 U.S. products revenue forecast
Jan 13Need To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying Shares
Dec 26Daiichi Sankyo/Esperion's cholesterol med approved in Switzerland
Dec 16Esperion Therapeutics appoints new COO
Dec 15Esperion Therapeutics' (NASDAQ:ESPR) Stock Price Has Reduced 58% In The Past Three Years
Nov 30Pooled analysis of Esperion's Nexletol shows significant reduction in cholesterol
Nov 13Esperion prices upsized $250M convertible debt offering
Nov 12Esperion: Analysis Of Prospects And Latest Earnings Call
Nov 08Shareholder Returns
| ESPR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.8% | -0.1% | 0.1% |
| 1Y | -81.3% | -3.1% | 13.5% |
Return vs Industry: ESPR underperformed the US Pharmaceuticals industry which returned -2% over the past year.
Return vs Market: ESPR underperformed the US Market which returned 13.7% over the past year.
Price Volatility
| ESPR volatility | |
|---|---|
| ESPR Average Weekly Movement | 14.2% |
| Pharmaceuticals Industry Average Movement | 10.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ESPR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: ESPR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 199 | Sheldon Koenig | https://www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
Esperion Therapeutics, Inc. Fundamentals Summary
| ESPR fundamental statistics | |
|---|---|
| Market Cap | US$142.15m |
| Earnings (TTM) | -US$208.39m |
| Revenue (TTM) | US$102.90m |
1.4x
P/S Ratio-0.7x
P/E RatioIs ESPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESPR income statement (TTM) | |
|---|---|
| Revenue | US$102.90m |
| Cost of Revenue | US$137.37m |
| Gross Profit | -US$34.47m |
| Other Expenses | US$173.92m |
| Earnings | -US$208.39m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.83 |
| Gross Margin | -33.50% |
| Net Profit Margin | -202.51% |
| Debt/Equity Ratio | -128.9% |
How did ESPR perform over the long term?
See historical performance and comparison